The second round of band procurement expanded to self-funded drugs to reduce drug prices has become an inevitable trend

December 6, 2019, just over a year from the first "4 plus 7" band procurement, the Joint Procurement Office through the convening of more than 100 related enterprises to open a symposium, announced that the second round of band procurement officially entered the key countdown, half a month to two months after the landing bidding work, and previously circulated on the Internet medical institutions reported 35 varieties have also been confirmed as the second round of volume procurement expansion of the final varietiesit is worth noting that the second round of band quantity procurement varieties not only in quantity than the first round of band quantity procurement varieties increased by 10, but also in the nature of the variety and structure of a great changecompared with the 2017 and 2019 editions of the National Health Insurance Directory can be found that the first round of "4 plus 7" and the subsequent expansion of the band volume procurement of 25 pilot varieties are all in the National Health Insurance Catalog of drugs, buta new round of strap purchase of 35 pilot varieties, there are already 5 for not included in the 2017 National Health Insurance Directory of self-funded drugsthis means that the impact of band purchases, which were originally intended to reduce the pressure on national health insurance funds in exchange for a price-for-money, is spreading beyond the national health-care directory after being piloted by out-of-pocket drugs01 with volume procurement, knife price!analysed the second round of the procurement of 35 pilot varieties, five of which were self-funded medicines not included in the National Health Insurance List for 2017Of these five varieties, Solina's new 2019 national health insurance regular catalog adjustment has been included, Acapo sugar through drug price negotiations finally into the 2019 National Health Insurance Catalog,the remaining three varieties Offort, Alyson and Hedarafi are not included in the two versions of the National Health Insurance Directoryand enterprise related people in an interview with E drug managers, said that the consultation has been collected by the relevant person in charge, these self-funded drugs will not be adjusted to participate in the second round of band procurement into the national health insurance directoryof the five varieties, Solina was successfully included in the 2019 national health insurance regular catalogue in August this year after a series of expert assessmentsRelevant data show that its consistency evaluation has reached four drugs, after entering the second round of band procurement, the related price competition is bound to be fierceThe situation facing the new Acapo sugar pesolia is even more serious, and it is subject to the double policy shock of the negotiation of national health insurance drug prices and the new round of national quantity procurementin a new round of national health insurance negotiations, Acapo sugar successfully entered the new version of the national health insurance catalogAlthough the price of Acapo sugar medical insurance negotiations is still confidential, but on December 3, Yunnan Province drug centralized procurement platform announced the recent changes in online drug information shows that Hangzhou China-U.SEast China Pharmaceutical Co., Ltdproduced Acapo sugar chewing tablets (50mg) price changes, from 2.6877 yuan / tablet to 1.1 yuan / tablet, a decrease of 59.11% Akapo Sacgen PharmaceuticalS, a domestic pharmaceutical company that has passed the consistency evaluation of generic drugs, only East China Pharmaceuticals and Green leaf Pharmaceuticals meters net city public hospital terminal data show that Bayer accounted for 69% of the market share of Acapo sugar, China and the United States accounted for 26%, Sichuan Green Leaf Baoguang Pharmaceuticals accounted for 5% According to the annual report of listed companies, East China Pharma Akpo Sugar's sales revenue in 2015 was over 1 billion yuan, sales revenue was over 1.5 billion yuan in 2016 and 2 billion yuan in 2017 entered into the national health insurance price negotiations at the same time, Acapo sugar into a new round of national band procurement of 35 pilot varieties, indicating that the relevant policy layer for the diabetes drug Akapo sugar has further price reduction expectations, Acapo sugar also faces greater pressure to reduce prices 02 with volume procurement to accelerate the arrival of the "patent cliff"
! In addition to Acapo Sugar and Solina, Adefoveester, Tadalafi and Alysson are all self-funded medicines, meaning that the battle for quantity has extended beyond the national health-care list Adeforster is used for hepatitis B According to the data of Minet, the overall domestic market for anti-hepatitis B virus drugs in 2017 has reached 15 billion yuan, from the market share of various varieties, Entikavir accounted for 67.25%, Adefoveester accounted for 11.97%, ramifedin accounted for 9.36%, Tibiftin accounted for 6.47%, tinofovite accounted for 4.96% Adelfore has formed a primary research and generic drug local pharmaceutical enterprises "1 plus 2" pattern, the price between the families will undoubtedly be very fierce tadalafi as an anti-ED drug In the domestic market, due to the late entry of Hedarafi into China and not well known to the Chinese people, the main share of the anti-ED drug market is still occupied by foreign-funded original drugs Sidinafi and domestic Sidina non-generic drugs In 2017, the overall market size of anti-ED drug PDE5 inhibitors in China reached 2.994 billion yuan, of which 2.23 billion yuan was in West Africa and 739 million yuan in Tadalafi Hedarafi has not been included in the national health insurance directory, and is also available in retail pharmacies to buy prescription drugs, its original pharmaceutical companies for Lilly, over the consistency of evaluation of the domestic generic drug enterprises have Qilu, Zhengdaya qing and Changchun Haiyue three, four fierce price killing, whether it will also have an impact on the retail pharmacy and other channels of drug prices, worthy of attention and An Lishengtan is on the high-pressure drug for the pulmonary arteries Pulmonary arterial hypertension drug Anlisheng Tan original research sales of nearly 1 billion U.S dollars a year, but because GSK and gilead original research patents just expired and expensive, according to rice net data, Anlisheng Tan domestic public hospital sales of only 310,000 yuan and domestic manufacturers in the list edi-sheng Tan and through the consistency evaluation of only two On December 13, 2018, Jiangsu Howsen An LishengTan was listed and adopted as a consistency evaluation On May 9, 2019, Zhengda Tianqing An Lishengtan was listed and adopted as a consistent evaluation two domestic generic drugs listed soon, An Lisheng Tan into the band procurement, which is also prompted to take the amount of procurement is not just to the listing of long-overdue original research drugs, some of the varieties just past the patent period may soon encounter the volume procurement, China's "patent cliff" will be with the help of the amount of procurement to accelerate the arrival 03 Regulating drug prices is also the core work
it is worth noting that although the initial key policy intention is to reduce the national health insurance catalog drug expenditure, reduce the financial burden of national health insurance, but with the band procurement-related experience gradually matured, the volume procurement is also becoming a new mechanism to regulate the management of drug prices, and in the provinces and cities pilot flowering everywhere in March last year, the national institutions "large-scale reform" dust settled, "one in four" National Health Insurance Bureau came out The newly established State Health Insurance Administration has merged the responsibilities of basic medical insurance and maternity insurance for urban workers and urban residents of the Ministry of Human Security; the responsibilities of the new agricultural association, which were previously the responsibilities of the Ministry of Health and Reform; the medical assistance responsibilities of the Ministry of Civil Affairs; the price management of drugs and medical services of the National Development and Reform Commission; the duties of bidding and procurement of medicines and supplies; the power to regulate medical service conduct and charges for medical insurance, and the responsibility for collecting medical insurance and maternity insurance expenses to the tax department and the second round of band procurement into the self-funded medicine, means that the National Health Insurance Administration not only by means of the method of carrying procurement, reduce the unreasonable high price of drugs in the national health insurance catalog, but also by the volume procurement to explore new ways of drug price management, in order to assume the responsibility of the past NDRC drug and medical service price management November 29, 2019, the Leading Group of the State Council to Deepen the Reform of the Medical and Health System issued a notice on a number of policy measures to further deepen the reform of the medical and health system with centralized procurement and use of drugs as a breakthrough, also stressed that for drugs not included in the scope of centralized procurement and use of national organizations, local governments should rely on the provincial centralized procurement platform for drugs, learn from the experience of centralized procurement and use of national organizations, adopt individual or cross-regional alliances, and other means to strengthen reform and innovation in the scope of procurement of drugs, entry standards, centralized procurement forms, etc at the same time, the notice encourages exploration to form reasonable prices by means of group procurement, joint procurement of specialized hospitals and procurement of medical complexes, and encourages the active participation of non-public medical institutions, social pharmacies and so on to jointly promote the formation of a market-oriented drug price formation mechanism in fact, Hebei Province, Wuhan City, Guangxi Province and other places have responded to the call to try to use the method of drug bidding in the local way of quantity procurement, and in the pilot varieties, Hebei Province, "two diseases" 15 pilot varieties have been in the scope of procurement of drugs innovation, varieties through consistency evaluation of less than 3 pharmaceutical production enterprises, allowing not to consistent evaluation of enterprises to participate in the bidding can imagine that the second round of the quantity procurement pilot varieties in the self-funded medicine opened a mouth, the future will also have self-funded drugs into the belt procurement pilot varieties, the volume procurement has become the official management of drug prices mechanism, whether in the national health insurance directory or outside the catalog, the relevant pharmaceutical companies should be prepared the original title: "Deep observation" the second round of the purchase of the fire has been burned to self-funded medicine, drug price reduction has become an inevitable trend!